BMS at ACR Convergence 2021

Intended for U.S. scientific audiences only.

The American College of Rheumatology Convergence 2021 meeting (ACR Convergence 2021) is an important opportunity to review and share the latest research for patients living with immune-mediated rheumatic diseases. 

Our Data at ACR Convergence 2021

Read more about our key data being presented at the meeting.

At ACR Convergence 2021, a total of 29 company-sponsored abstracts demonstrating the breadth and depth of the company’s robust rheumatology pipeline and portfolio will be presented. We continue to expand upon the foundation laid 20 years ago in rheumatoid arthritis, as we pursue pathbreaking science across other immune-mediated diseases such as psoriatic arthritis and lupus.

Our Science   

Our diverse, promising portfolio and pipeline is driven by our focus on offering innovative medicines that we hope will transform patients’ lives. Read about how our scientists are addressing some of the most challenging diseases of our time and advancing research across numerous immune-mediated diseases.

Destination: The Impact of Precision Medicine in Disease Management for People With Immune-Mediated Diseases >

Brian Gavin, vice president, development program lead, discusses precision medicine for immune-mediated diseases, including rheumatoid arthritis and systemic lupus erythematosus.

Lupus: Treatments, Research and Bristol Myers Squibb’s Dedication to Patients – A Q&A with Subhashis Banerjee >

Subhashis Banerjee, vice president & disease area head, Rheumatology and Dermatology, explains how we are leaving no stone unturned in our approach to lupus research. 

Our Precision-Focused Approach in Rheumatoid Arthritis and Beyond: A Q&A With Dr. Sean E. Connolly >

Sean E. Connolly, executive director, head of Clinical Evaluation and Collaborations, explains our precision medicine research approach and shares a video on the potential role of biomarkers.

Pursuing Innovative Approaches to Advance Research for Psoriatic Disease >

Shalabh Singhal, executive director, development program lead, Rheumatology, explains how by targeting the tyrosine kinase 2 (TYK2) pathway, researchers can further our understanding of how to improve care for psoriatic disease.


Our research in immunology and rheumatology spans a number of diseases and pathways. Learn more below.

Biomarkers in Rheumatoid Arthritis Infographic >

Learn more how biomarkers in rheumatoid arthritis can provide clues to diagnosis, insights into overall prognosis and have the potential to inform treatment strategies.

TYK2 Pathway Infographic >

Learn about the scientific mechanism behind the tyrosine kinase 2 (TYK2) pathway and its role in immune-mediated diseases.  

Psoriatic Arthritis Infographic >

Learn more about psoriatic arthritis, its symptoms and its potential impact on patients. 

Rheumatoid Arthritis Infographic >

Learn more about rheumatoid arthritis, an immune-mediated disease that affects patients worldwide.

Lupus Infographic >

Learn more about systemic lupus erythematosus (SLE) and how it can impact patients around the world.

Juvenile Idiopathic Arthritis (JIA) Infographic >

Learn more about JIA, its symptoms and effects on pediatric patients worldwide.

Ankylosing Spondylitis Infographic >

Learn more about ankylosing spondylitis, a type of chronic inflammatory arthritis that primarily affects the spine. is a resource for U.S. healthcare professionals to learn more about our recruiting clinical trials as well as the breadth of our research.